R estenosis after successful percutaneous transluminal coronary angioplasty is mediated in part by an uncontrolled proliferation of smooth muscle cells that migrate into the intima, proliferate, and encroach into the lumen.' The development of the neointimal lesion is the end point of the natural healing process that has been initiated by vascular injury of the nonatheromatous segment of the dilated artery.1 At- tempts to attenuate the development of intimal hyperplasia largely have been unsuccessful.
Angiopeptin, a synthetic cyclic octapeptide, is a somatostatin analogue that inhibits growth hormone release.2'3 Angiopeptin possesses significant antiproliferative effects in tissue cultures of neoplastic cells3 and inhibits myointimal hyperplasia after endothelial denudation injury in rats,4 rabbits,5,6 and nonhuman primates. 7 We tested angiopeptin in the swine model of restenosis because of 
Histopathological Analysis
Both the control (Fig 1A) and angiopeptin (Fig 1B to  1D ) groups exhibited eccentric disruption of the media, creating an adventitial crater with an exposed external elastic lamina. In the angiopeptin group, the neointimal response at the fractured medial ends was reduced 14 days after balloon injury.
Morphometric Analysis
The maximal intimal thickness and the residual lumen are shown in Fig 2. The maximal intimal thickness was decreased significantly and the residual lumen was significantly greater at 14 and 28 days after balloon injury in the angiopeptin group. Discussion Angiopeptin significantly limits the development of intimal hyperplasia following overstretch-balloon injury in this swine model. These effects of angiopeptin appeared to be due to an inhibition of smooth muscle cell proliferation, migration from the media, or both and thus resulting in a reduced intimal mass.
Although the beneficial effects of angiopeptin were detected 2 weeks after completion of angiopeptin treatment, the maximal intimal thickness of the neointima increased within 2 weeks after completion of therapy, suggesting the beginning of late neointimal growth.
The mechanism by which angiopeptin inhibits the development of neointima is unclear, although the ability of angiopeptin to attenuate smooth muscle cell proliferation in vitro, in the absence of systemic growth hormone, suggests that the beneficial effects of angiopeptin are unrelated to the somatostatin inhibitory effects on growth hormone. It is likely that angiopeptin directly inhibits mechanisms of smooth muscle cell replication at the subcellular level.'4 Angiopeptin has been shown to activate a membrane-bound tyrosine phosphate that deactivates tyrosine kinase receptors common to known growth factors, such as epidermal growth factor, fibroblast growth factor, and plateletderived growth factor.14 Lack of smooth muscle cell proliferation and/or migration with angiopeptin treatment (Fig 1) of potential inhibitors of restenosis should be proven effective in either swine or nonhuman primate models before initiating large-scale clinical trials.
